Oruka Therapeutics CMO Joana Goncalves Sells $707K of Stock
Joana Goncalves, CMO, sold 7,000 shares of Oruka Therapeutics, Inc. at $99.52 to $105.86 a share (average $100.96) in 6 transactions, worth $707K in total on Nov 16, 2026. Shares held after the trade: 31,771 (-1.5%).
Oruka Therapeutics SVP, Finance Arjun Agarwal Sells $1.05M of Stock
Arjun Agarwal, SVP, Finance, sold 10,000 shares of Oruka Therapeutics, Inc. at $101.98 to $107.00 a share (average $104.97) in 6 transactions, worth $1.05M in total on Nov 12, 2026. Shares held after the trade: 14,219 (-0.7%).
Oruka Therapeutics Insider Kristine M. Ball Sells $1.89M of Stock
Kristine M. Ball sold 18,000 shares of Oruka Therapeutics, Inc. at $102.10 to $106.98 a share (average $104.93) in 6 transactions, worth $1.89M in total on Nov 12, 2026. Shares held after the trade: 0 (-100.0%).
Oruka Therapeutics reported a net loss of $123.0 million for the nine months ended September 30, 2026, driven by $126.1 million in research and development expenses. The company significantly strengthened its balance sheet during the period, ending with $1.23 billion in total assets following a major common stock offering in April 2026 and ATM program activity.
Oruka Therapeutics CEO Lawrence Otto Klein Sells $2.39M of Stock
Lawrence Otto Klein, CEO, sold 25,000 shares of Oruka Therapeutics, Inc. at $94.77 to $98.40 a share (average $95.60) in 5 transactions, worth $2.39M in total on Nov 2, 2026. Shares held after the trade: 923,128 (-0.0%).
Oruka Therapeutics announced positive Week 16 results from its Phase 2b EVERLAST-B clinical trial of ORKA-001 in patients with moderate-to-severe plaque psoriasis. The trial met its primary endpoint with 61% of patients in the high-dose (600 mg) group achieving complete skin clearance (PASI 100) compared to 0% for placebo, supporting the planned initiation of Phase 3 trials in the first half of 2027.
Oruka Therapeutics General Counsel Paul T. Quinlan Sells $707K of Stock
Paul T. Quinlan, General Counsel, sold 9,000 shares of Oruka Therapeutics, Inc. at $74.90 to $79.49 a share (average $78.53) in 5 transactions, worth $707K in total on Oct 20, 2026. Shares held after the trade: 29,995 (-9.1%).